[Factors associated with an abnormal ankle-braquial index in a cohort of patients with HIV-1 infection].
OBJECTIVE
An abnormal ankle-braquial index (ABI) has been related to a higher vascular mortality in the general population. People with HIV infection have a higher prevalence of abnormal ABI than general population. Our aim was to study that prevalence in a cohort of patients with HIV chronic infection and associated factors with an abnormal ABI.


METHODS
ABI was calculated consecutively in all the patients who agreed to participate. Abnormal ABI was defined as that lower than 0.9 or higher than 1.3. Demographic variables and those related to vascular risk, HIV infection status and antiretroviral therapy were assessed.


RESULTS
231 patients collaborated in the study, and 25% of them had abnormal ABI (<0.9 in only 3 patients). Age, hypertension, lipid lowering agents use, vascular risk using Framingham equation, proportion of AIDS, CD4 nadir, years with the infection and protease inhibitors use were greater in the group with abnormal ABI. In logistic regression, lipid lowering agents use (OR: 0.39, CI95%: 0.16-0.94) and protease inhibitors use (OR: 2.59, CI95%: 1.33-5.05) remained in the model.


CONCLUSIONS
Protease inhibitors use is associated with abnormal ABI, overall with an ABI greater than 1.3.
Salas
Daniel
D
Distrito Sanitario de la Costa del Sol, Málaga, Spain.
Olalla
Julián
J
Del Arco
Alfonso
A
De La Torre
Javier
J
Prada
José Luis
JL
Pombo
Marta
M
García-Alegría
Javier
J
Martos
Francisco
F
D000328:Adult; D055109:Ankle Brachial Index; D015331:Cohort Studies; D016001:Confidence Intervals; D003627:Data Interpretation, Statistical; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000453:epidemiology*; D015497:HIV-1; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D011480:Protease Inhibitors / Q000627:therapeutic use; D012307:Risk Factors
D011480:Protease Inhibitors